Radnostix Acquires Lucerno Dynamics Assets Expanding Radiopharma Medical Device Portfolio

Rhea-AI Summary

Radnostix (OTCQB: INIS) closed the acquisition of key assets from Lucerno Dynamics, including the LARA System, ELLEXA Explorer software and related IP. The platform supports visualization, uptake monitoring and dosimetry for IV radiopharmaceuticals, including real-time extravasation detection, and has been used in nearly 50,000 clinical administrations worldwide.

Radnostix plans to integrate these technologies into its radiopharma medical device portfolio to support theranostics delivery, drug uptake monitoring and potential pairing with drug injection and auto-infusion systems.

Positive

• Acquisition of LARA System, ELLEXA Explorer and related IP completed
• Portfolio used in nearly 50,000 radiopharmaceutical administrations globally
• Expands Radnostix’s radiopharma medical device and monitoring offerings
• Supports strategy to serve theranostics delivery and administration market

Negative

• None.

News Market Reaction – INIS

-1.96%

-1.96% News Effect

On the day this news was published, INIS declined 1.96%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IDAHO FALLS, Idaho, July 2, 2026 /PRNewswire/ -- Radnostix, Inc. (OTCQB: INIS) ("Radnostix" or the "Company"), a leader in radioisotope production and nuclear medicine solutions, today announced the successful closing of its acquisition of key assets from Lucerno Dynamics, LLC, including the LARA® System technology platform, ELLEXA® Explorer software and associated intellectual property.

The product line was originally developed to identify, improve dosimetry of, and reduce the frequency of extravasations of IV administered radiopharmaceuticals. Recently, the product line expanded to include a Real-Time Visualization feature. Clinicians can now stop extravasations as they happen before they become a serious concern in the theranostics administration.

The acquired portfolio of IP carries with it additional applications in uptake, dosimetry, quantification, and integration into auto-infusion drug delivery systems. This strategic acquisition enables Radnostix to develop the IP into new product  offerings in radiopharmaceutical and nuclear medicine applications by developing practical delivery and monitoring solutions for both new and existing market participants.

"The Lucerno team have developed a broad  group of intellectual property and we are proud to carry the baton from here and expand the world of applications for their IP. I'd like to thank the team at Lucerno for their trust in our team to execute and deliver long term viability for their IP," said Shahe Bagerdjian, CEO of Radnostix. "This acquisition marks a significant milestone in Radnostix's strategy to become a comprehensive solutions provider in the rapidly growing theranostics delivery & administration market. The LARA and ELLEXA technologies and IP will allow us to create innovative, user-friendly tools — drug uptake monitoring, dosimetry systems, and potentially pair with drug injection systems — that lower barriers to entry for clinics and improve safety and efficiency in radiopharmaceutical administration. We are excited to integrate these products and future capabilities into our growing device portfolio that better positions Radnostix as the go-to partner for RLT administration clinics."

"I am extremely thankful to the Lucerno team, a dedicated group of nuclear medicine leaders and advisers, and our investors for their extensive work to develop this amazing patient safety product, the Lara System. Lara adds just 1-2 minutes to the radiopharmaceutical administration procedure and patients love the assurance that Lara provides," said Ron Lattanze, CEO of Lucerno Dynamics. He added, "The Lara System and Ellexa software has been clinically proven in nearly 50,000 administrations in top centers across Australia, Singapore, Japan, Europe, and throughout the United States. We believe this product is a powerful tool to help improve patient safety in the rapidly growing and life-saving world of nuclear medicine and we look forward to supporting the Radnostix team to ensure every nuclear medicine patient experiences the confidence that comes from having the Lara System used during their radiopharmaceutical experience."

About Radnostix (formerly International Isotopes Inc.): Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. For more information, visit www.radnostix.com.

Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to, statements regarding the Company's current expected financial impact from the termination of the APA, the estimated value of the DUF6 Plant and related assets, statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2025. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and Radnostix, Inc. and the Company undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Radnostix Contact: 
ir@intisoid.com
radnostix.com

View original content:https://www.prnewswire.com/news-releases/radnostix-acquires-lucerno-dynamics-assets-expanding-radiopharma-medical-device-portfolio-302816984.html

SOURCE International Isotopes Inc.

FAQ

What did Radnostix (OTCQB: INIS) announce on July 2, 2026 about Lucerno Dynamics?

Radnostix announced it closed the acquisition of key assets from Lucerno Dynamics, including the LARA System, ELLEXA Explorer software and associated intellectual property. According to Radnostix, these assets will expand its radiopharmaceutical delivery and monitoring device portfolio for nuclear medicine and theranostics applications.

What is the LARA System acquired by Radnostix (INIS) and how is it used?

The LARA System is a radiopharmaceutical administration monitoring platform designed to improve dosimetry and reduce IV extravasations. According to Lucerno, it now includes real-time visualization and has been clinically used in nearly 50,000 administrations across major centers in the US, Europe, Australia and Asia.

How will the Lucerno Dynamics acquisition affect Radnostix’s theranostics strategy?

The acquisition supports Radnostix’s strategy to become a comprehensive solutions provider in theranostics delivery and administration. According to Radnostix, LARA and ELLEXA technologies may enable new tools for drug uptake monitoring, dosimetry and potential pairing with injection or auto-infusion systems, targeting RLT administration clinics.

What clinical experience exists with the LARA System and ELLEXA software before Radnostix’s INIS deal?

According to Lucerno, the LARA System and ELLEXA software have been clinically proven in nearly 50,000 radiopharmaceutical administrations. These procedures were performed at top nuclear medicine centers in Australia, Singapore, Japan, Europe and the United States, focusing on patient safety and extravasation detection.

How does the Radnostix INIS acquisition aim to improve radiopharmaceutical patient safety?

The acquired technology is designed to detect and reduce radiopharmaceutical extravasations and improve dosimetry. According to Lucerno, LARA adds only 1–2 minutes to administration while offering real-time visualization and assurance to patients, supporting safer radiopharmaceutical and theranostics treatments in nuclear medicine clinics.

What existing businesses does Radnostix (INIS) operate alongside the Lucerno assets?

Radnostix manufactures sodium iodide I-131 drug product, supplies radioisotope APIs for theranostics clients, and produces calibration and reference standards under the RadQual brand. According to Radnostix, integrating LARA and ELLEXA adds complementary medical device capabilities to its broader nuclear medicine and radiopharmaceutical portfolio.